F25P preproinsulin abrogates the secretion of pro-growth factors from EGFRvIII cells and suppresses tumor growth in an EGFRvIII/wt heterogenic model
详细信息 查看全文
- 作者：Jian-wei Weia ; 1 ; Jing-qiu Cuib ; 1 ; Xuan Zhouc ; Chuan Fangd ; Yan-li Tane ; Lu-yue Chena ; Chao Yanga ; Ming Liub ; Chun-sheng Kanga ; kang97061@tmu.edu.cn" class="auth_mail" title="E-mail the corresponding author
- 关键词：EGFRvIII ; F25P preproinsulin ; External secretion ; Glioblastoma
- 刊名：Cancer Letters
- 出版年：2016
- 出版时间：28 September 2016
- 年：2016
- 卷：380
- 期：1
- 页码：1-9
- 全文大小：5139 K
文摘
- •
EGFRvIII is a kind of “driving” cell for heterogeneity maintenance and tumor progression in GBM.
- •
EGFRvIII external secretion has obvious supporting role in the entire tumor growth in vitro and in vivo.
- •
Signal peptidase in the endoplasmic reticulum (ER) membrane may be a suitable therapeutic target for GBM intervention.